INTERACTION OF HIV MEDICATIONS WITH OPIATE THERAPY MEDICATIONS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是测试丁丙诺啡-纳洛酮与治疗HIV疾病的药物的相互作用。如果参与者对海洛因或处方药上瘾，并且目前没有接受药物滥用治疗，他们将有资格参加这项研究。研究对象必须在加入研究之前至少两周服用有助于预防戒断症状的Suboxone疗法。预计报名人数为70人，艾滋病药物将服用5天。 这项研究将要求RS以门诊患者的身份参加，并入院进行血液和尿液采样(两个会议各1-2个晚上)。RS还必须同意除星期日外，每天到诊所服药和进行健康检查。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is test the interactions of buprenorphine-naloxone, and medications to treat HIV disease. The participants will be eligible for this study if they have an addiction to heroin or prescription medications and are not currently receiving substance abuse treatment. The research subject must be taking Suboxone therapy, which helps prevent withdrawal symptoms, for at least 2 weeks before joining the study. The anticipated enrollment is 70 and the HIV drugs will be taken for 5 days. This study will require that RS participate as an outpatient and be admitted to the hospital for blood and urine sampling sessions (1-2 nights for each of the two sessions). The RS must also agree to daily visits to the clinic, except for Sundays, to take medication and have a health examination.